Is a pathway to defeat cancer coming soon?

Groundbreaking research shows that certain drugs developed for asthma and allergies are showing significant promise in treating cancer, potentially improving outcomes for patients with aggressive tumors .

The connection lies in shared immune pathways. Conditions like asthma are driven by specific types of inflammation, and it's now clear that some cancers exploit these very same pathways to grow and evade the immune system. By repurposing allergy and asthma medications to block these pathways, scientists are finding they can "reprogram" the immune system to fight cancer more effectively.

Promising Repurposed Drugs in Research
Asthma & Allergies
Blocks the CysLTR1 pathway that tumors use to turn immune cells (neutrophils) into cancer allies. Preclinical studies show it can slow tumor growth, improve survival, and restore response to immunotherapy in resistant cancers like triple-negative breast cancer .
Anti-IL-4 / Anti-IL-4 Receptor Antibodies 
Asthma & Allergies (e.g., Dupilumab)
A study combining an IL-4 blocking antibody with standard immunotherapy for lung cancer showed significant tumor reduction in one out of six treatment-resistant patients, with one patient's cancer nearly disappearing .
Leukotriene Receptor Antagonists (LTRAs) 
Asthma & Allergic Rhinitis
A large population study found that asthma patients treated with LTRAs (especially with antihistamines) had a significantly lower risk of developing lung cancer compared to those on other allergy medications .

Important Considerations and Risks
While these findings are exciting, the research is still in its early stages. Most of these results come from laboratory studies, animal models, or retrospective patient data analyses, and require further validation in human clinical trials before becoming standard treatments .
Some asthma medications have also been linked to increased risks, highlighting the complexity of these immune pathways:
Dupilumab: While associated with lower all-cause mortality in asthma patients, a large study found a higher risk of lymphoma (especially T-cell and NK-cell lymphomas) in patients taking this drug .
Glucocorticoids (Corticosteroids): These common anti-inflammatory drugs were associated with a higher risk of lung cancer in patients with allergic diseases .
A New Therapeutic Target: CCL20-CCR6 Axis

Beyond drug repurposing, researchers are exploring new therapeutic targets. One promising area is the CCL20-CCR6 chemokine axis. This pathway is highly active in both allergic asthma and non-small cell lung cancer (NSCLC), promoting inflammation and tumor growth. Studies suggest that blocking this axis with antibodies or other inhibitors could potentially treat both conditions, though the exact mechanisms are still being investigated .

We hope something emerges soon to provide hope and succour to the patients

By Jamuna Rangachari